febuxostat has been researched along with dactinomycin in 1 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (dactinomycin) | Trials (dactinomycin) | Recent Studies (post-2010) (dactinomycin) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 19,045 | 355 | 969 |
| Protein | Taxonomy | febuxostat (IC50) | dactinomycin (IC50) |
|---|---|---|---|
| RAD51 | Homo sapiens (human) | 32.1 | |
| Growth factor receptor-bound protein 2 | Homo sapiens (human) | 5 | |
| Discoidin domain-containing receptor 2 | Homo sapiens (human) | 9 | |
| Growth factor receptor-bound protein 2 | Mus musculus (house mouse) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for febuxostat and dactinomycin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |